ImproveCareNow Research


ICN Research Explained: Travel Time to Treating Center is Associated with Diagnostic Delay in Pediatric Inflammatory Bowel Disease

Delayed diagnosis of inflammatory bowel disease (IBD) leads to prolonged symptoms and worse long-term outcomes. We sought to evaluate whether race, ethnicity, disease type, and social factors are associated with delayed diagnosis of pediatric IBD.


ICN Research Explained: The association between erythema nodosum and pyoderma gangrenosum and pediatric inflammatory bowel disease

The objectives of this study are to estimate rates and identify factors associated with erythema nodosum (EN) and pyoderma gangrenosum (PG) in pediatric patients with inflammatory bowel disease (IBD).


ICN Research Explained: High body mass index and response to anti-tumor necrosis factor therapy in pediatric Crohn’s disease

Obesity is common among patients with pediatric Crohn's disease (PCD). Some adult studies suggest obese patients respond less well to anti-tumor necrosis factor (TNF) treatment. This study compares anti-TNF response and anti-TNF levels between pediatric patients with normal and high body mass index (BMI).


Trends in ICN and IBD Research - Notes from the Field

ImproveCareNow Research Committee member and pediatric IBD psychologist, Jennie David PhD, recently shared her answers to some questions about the state of IBD research, emerging trends in ICN Research, significant recent discoveries, and the value of being involved for psychosocial professionals.


ICN Research Explained: Diagnosis change in pediatric inflammatory bowel disease

This study aims to characterize pediatric inflammatory bowel disease (IBD) patients who change diagnosis and describe the characteristics of that change.


ICN Research Explained: Physicians’ Explanatory Models of Pediatric Inflammatory Bowel Disease: A Qualitative Interview Study

This study characterized the explanatory models used by pediatric gastroenterologists when explaining inflammatory bowel disease (IBD) to children.


ICN Research Explained: Is it "all in the bag?" Multidisciplinary perspectives on ostomy surgery in pediatric IBD across the ImproveCareNow network

Pediatric inflammatory bowel disease (IBD) is a chronic illness with various treatments, including ostomy surgery. Ostomy‐related medical decision‐making (MDM) is complex for multidisciplinary healthcare professionals (HCPs). This study sought to understand national multidisciplinary HCPs' perceptions about pediatric IBD ostomy surgery in the United States.


Sleep, Pain, Anxiety, Depression, and Fatigue in Pediatric IBD

Symptoms including Sleep, Pain, Anxiety, Depression, and low Energy/fatigue, also known as the SPADE pentad, can be debilitating for people living with IBD. Research with adults with IBD has found that SPADE symptoms can be particularly distressing and disruptive, even for patients in disease remission. SPADE symptoms are believed to be multidimensional, complex, and multifactorial in nature, suggesting a number of interacting clinical, demographic, and psychosocial characteristics contribute to symptom severity. However, we have yet to explore the relationships among these symptoms in the pediatric population living with IBD.

A new research study seeks to explore SPADE symptoms in teens with IBD.


ICN Research Explained: Biosimilars for Pediatric Patients With Inflammatory Bowel Disease: Pediatric Gastroenterology Clinical Practice Survey

Why was this study done?

Pediatric patients with inflammatory bowel disease (IBD), including Crohn’s Disease and ulcerative colitis, who take biologic medications (like infliximab and adalimumab) have decreased hospitalizations, surgery rates, and improved quality of life. However, biologic medicines are expensive. Biosimilars are similar biological therapies that are just as safe and effective as the original biologic medication, although they are often less expensive. There are currently two medications (infliximab/Remicade and adalimumab/Humira) used to treat IBD that have biosimilars available. Despite the cost savings, the utilization of biosimilars in the treatment of IBD has been low. The exact reasons why the utilization of biosimilars is low is not well known or well-studied.

The objective of this study was to evaluate pediatric gastroenterologists’ perspectives of biosimilars and to evaluate factors that impact pediatric gastroenterologists’ comfort level with prescribing biosimilars.



1  2  3  4  5  6  7  8  9  Next →
if page.is_commentable? include "comments" endif

Built by Veracity Media on NationBuilder